Eli Lilly and Clinical Research

Selected news for the company - Eli Lilly, and the healthcare topic - Clinical Research. We have 89 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
8/10/2021 Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials | Business Wire Business Wire ... for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen , AstraZeneca , and Eli Lilly and Company , and approximately 4,000 research sites across 65 countries. Care Access , having ... number of years trying to understand this question: why is clinical research still such a devastating bottleneck on drug development?‚Au said Ralph Passarella, CEO of Reify Health. ‚AuIt was painfully obvious that slow, unpredictable ...
8/10/2021 Reify Health Raises $220 Million to Eliminate Waiting in Clinical Trials Business Wire ... for optimizing patient recruitment and enrollment, and is used by top-20 global biopharma companies such as Amgen , AstraZeneca , and Eli Lilly and Company , and approximately 4,000 research sites across 65 countries. Care Access , having ... number of years trying to understand this question: why is clinical research still such a devastating bottleneck on drug development?‚Au said Ralph Passarella, CEO of Reify Health. ‚AuIt was painfully obvious that slow, unpredictable ...
7/30/2021 Eli Lilly's New Compliance Chief on His Priorities - WSJ The Wall Street Journal ... Eli Lilly & Co.‚Aos new compliance chief, Alonzo Weems.Mr. Weems succeeded Melissa Stapleton Barnes, who retired from the Indianapolis-based company in June after about nine years as its chief ethics and compliance officer .As an Eli Lilly employee since 1997, Mr. Weems is deeply familiar with the company‚Aos core businesses. Among his prior roles, he served as a lawyer supporting clinical research in oncology and as a ...
6/10/2021 Sensorion Appoints Nora Yang as CSO ... Eli Lilly & Co. In particular, she was instrumental in the development of clinical stage gene therapies to treat monogenic diseases. In her new role, Nora Yang will be based in the U.S. and will lead the preclinical organization at Sensorion Research Laboratories in Montpellier, France. She will also spearhead the development of collaborations between fundamental and clinical research, including working with Sensorion's partner, Institut Pasteur."I am delighted to welcome ...
6/10/2021 Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer ... Eli Lilly & Co. In particular, she was instrumental in the development of clinical stage gene therapies to treat monogenic diseases. In her new role, Nora Yang will be based in the U.S. and will lead the preclinical organization at Sensorion Research Laboratories in Montpellier, France. She will also spearhead the development of collaborations between fundamental and clinical research, including working with Sensorion‚Aos partner, Institut Pasteur.‚AuI am delighted to ...
4/14/2021 Senior Data Engineer - Remote Jobs Feed ... Eli Lilly & Company. Our team is made up of a diverse group of researchers, entrepreneurs, technologists, data experts, and healthcare-obsessed professionals working to eliminate some of the biggest challenges in clinical research. We care about the people who care for people‚A¶and we have fun while doing it. Our unique, rapidly growing data streams are enabling unique opportunities to manage clinical trials more efficiently and predictably. The Data ...
3/18/2021 Anima attracts Takeda in potential multibillion-dollar deal | 2021-03-18 | BioWorld BioWorld Small-molecule mRNA translation expert Anima Biotech Inc. has landed a significant new preclinical research deal with Takeda Pharmaceutical Co. Ltd. , covering as many as six programs for genetically defined neurological diseases. The deal starts ... second big pharma partnership after landing a multiyear deal with Eli Lilly and Co. to develop translation inhibitors for selected neuroscience targets in July 2018. As with that deal, the Takeda agreement will see Anima ...
12/27/2020 Medical Affairs ‚Äì Medical Writing - Hire Fresher Clinical Research / By HireFresher / December 27, 2020 December 27, 2020Job title: Medical Affairs ‚Ai Medical Writing Company: Eli Lilly Job description : At Lilly, we unite caring with discovery to make life better for people around the world. We are a global healthcare leader headquartered in Indianapolis, Indiana. Our 39,000 employees around the world work to discover and bring life-changing medicines to those who need them, improve the understanding ...
10/16/2020 Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer | Business Wire Business Wire ... that we believe could have a meaningful impact for more lung cancer patients,” said Dr. Vicki Goodman, vice president, oncology clinical research, Merck Research Laboratories. “Updated data from our anti-CTLA-4 antibody quavonlimab in ... KEYNOTE-021 (Cohort G) trial was conducted in collaboration with Eli Lilly and Company, the makers of pemetrexed (ALIMTA ® ).Quavonlimab (anti-CLTA-4) in Combination With KEYTRUDA: Phase 1/2 Results in Advanced NSCLC (Poster TS01.02 ...
10/16/2020 FiercePharmaAsia—COVID-19 drug manufacturing; Roche's China slowdown; Astellas' Iota buy | FiercePharma FiercePharma Oct 16, 2020 10:40am Takeda, CSL, Eli Lilly, Fujifilm, Roche and Astellas made our news this week. (Google) Takeda and CSL Behring are scaling up manufacturing of their coronavirus hyperimmune drug, but its reliance on ... could make this year. Featured Webinar How to Streamline Your Clinical Research Organization's Processes End to End Learn how implementing one platform leads to data consistency and ultimately facilitate faster clinical trials while reducing overall ...
10/16/2020 ... that we believe could have a meaningful impact for more lung cancer patients,” said Dr. Vicki Goodman, vice president, oncology clinical research, Merck Research Laboratories. “Updated data from our anti-CTLA-4 antibody quavonlimab in ... KEYNOTE-021 (Cohort G) trial was conducted in collaboration with Eli Lilly and Company, the makers of pemetrexed (ALIMTA ® ).Quavonlimab (anti-CLTA-4) in Combination With KEYTRUDA: Phase 1/2 Results in Advanced NSCLC (Poster TS01.02 ...
10/16/2020 Merck Presents Three-Year Survival Data for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy and Updated Phase 1/2 Data for Investigational Quavonlimab (MK-1308) in Combination With KEYTRUDA in Advanced Non‑Small Cell Lung Cancer Business Wire ... that we believe could have a meaningful impact for more lung cancer patients,” said Dr. Vicki Goodman, vice president, oncology clinical research, Merck Research Laboratories. “Updated data from our anti-CTLA-4 antibody quavonlimab in ... KEYNOTE-021 (Cohort G) trial was conducted in collaboration with Eli Lilly and Company, the makers of pemetrexed (ALIMTA ® ).Quavonlimab (anti-CLTA-4) in Combination With KEYTRUDA: Phase 1/2 Results in Advanced NSCLC (Poster TS01.02 ...
10/8/2020 Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen PR Newswire Incyte logo. (PRNewsFoto/Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company) Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company) (PRNewsfoto/Eli Lilly and Company) INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and ... NIH) presented today by John Beigel, M.D., associate director for clinical research in the Division of Microbiology and Infectious Diseases at NIAID. These data were presented at a special International Society for Influenza and other ...
10/8/2020 Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen | Benzinga Benzinga INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY ) and Incyte (NASDAQ: INCY ) are sharing additional data showing baricitinib in combination with remdesivir reduced time to recovery and improved clinical outcomes for patients ... NIH) presented today by John Beigel, M.D., associate director for clinical research in the Division of Microbiology and Infectious Diseases at NIAID. These data were presented at a special International Society for Influenza and other ...
10/8/2020 Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen | BioSpace BioSpace ... Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen INDIANAPOLIS , Oct. 8, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) are sharing additional data showing ... NIH) presented today by John Beigel, M.D., associate director for clinical research in the Division of Microbiology and Infectious Diseases at NIAID. These data were presented at a special International Society for Influenza and other ...
10/7/2020 Innovent Announces the Effectiveness of the Expanded Global Collaboration with Lilly on TYVYT® (sintilimab injection) Following the Expiration of HSR Act Waiting Period PR Newswire ... of 1976, as amended (the "HSR Act"), in connection with the previously announced global expansion collaboration agreement between Innovent and Eli Lilly and Company ("Lilly") for TYVYT® (sintilimab injection). The agreement now becomes effective immediately ... 10 registrational or pivotal clinical trials. Meanwhile, Innovent is conducting clinical research studies on TYVYT® (sintilimab injection) worldwide. About Innovent Inspired by the spirit of "Start with Integrity, Succeed through Action," Innovent's mission is to ...
10/6/2020 ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board Globe Newswire ... Clinical Research, at the Massachusetts General Hospital Cancer Center. He co-founded and served on the Board of Directors of Loxo Oncology until its acquisition by Eli Lilly and Company. He currently serves on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1 and PO1 grants. He is an author of many research articles ...
10/6/2020 ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board ... Clinical Research, at the Massachusetts General Hospital Cancer Center. He co-founded and served on the Board of Directors of Loxo Oncology until its acquisition by Eli Lilly and Company. He currently serves on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1 and PO1 grants. He is an author of many research articles ...
10/6/2020 ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board BioSpace ... Clinical Research, at the Massachusetts General Hospital Cancer Center. He co-founded and served on the Board of Directors of Loxo Oncology until its acquisition by Eli Lilly and Company. He currently serves on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1 and PO1 grants. He is an author of many research articles ...
10/6/2020 ALX Oncology Names Leading Oncology Experts to Scientific Advisory Board - GuruFocus.com ... Clinical Research, at the Massachusetts General Hospital Cancer Center. He co-founded and served on the Board of Directors of Loxo Oncology until its acquisition by Eli Lilly and Company. He currently serves on the Board of Directors of Clovis Oncology and Checkmate Pharmaceuticals. Dr. Flaherty has been awarded numerous grants from the National Cancer Institute, including K23, RO1 and PO1 grants. He is an author of many research articles ...
10/5/2020 Demand grows for chief research information officers as role evolves - Modern Healthcare Modern Healthcare ... Medicine. Though his title is CIO, Tachinardi effectively serves as CRIO, and actually holds a dual appointment as dean of clinical research informatics at IU. He also was CRIO at a previous job at the ... similar relationships with external partners, including drug developers Roche and Eli Lilly. "I oversee the team that provides resources and support to them," Tachinardi said. Genomic complexity Even in the year and a half that ...
10/2/2020 Ex-Ipsen boss de Garidel takes the helm at AZTherapies | FierceBiotech FierceBiotech ... manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy. Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical ... at the French pharma company. He began his career at Eli Lilly, where he held various roles spanning sales, marketing, finance and human resources, before moving onto Amgen, where he started out as its chief ...
10/1/2020 Care Access Research Partners on Revolutionary Mobile Clinical Trial for COVID-19 Treatment Business Wire BOSTON–(BUSINESS WIRE)–Care Access Research, the leader in rapid development and management of high-performing clinical research sites, announced that it is collaborating with global healthcare leader Eli Lilly and Company. Care Access Research is helping Lilly manage the first-of-its-kind system of decentralized, mobile clinical COVID-19 trials as part of the partnership. The BLAZE-2 phase III trial of Lilly’s monoclonal antibody (mAb) LY-CoV555 ...
9/28/2020 TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma (HCC) PR Newswire ... history of HBV infection, which is a quite different feature from HCC in the European and American countries. Therefore, continued clinical research in treating HCC is of great importance in China . The ORIENT-32 study ... commercialization. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Alector, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit: www.innoventbio.com . Note: TYVYT® (sintilimab ...
9/28/2020 TYVYT® (Sintilimab Injection) in Combination with BYVASDA® (Bevacizumab Injection) ORIENT-32 Study Met Its Primary Endpoints of Progression-Free Survival and Overall Survival in the First-Line Tre... | Markets Insider Business Insider ... history of HBV infection, which is a quite different feature from HCC in the European and American countries. Therefore, continued clinical research in treating HCC is of great importance in China . The ORIENT-32 study ... commercialization. The company has also entered into strategic collaborations with Eli Lilly and Company, Adimab, Incyte, Alector, MD Anderson Cancer Center, Hanmi and other international partners. For more information, please visit: www.innoventbio.com. Note: TYVYT® (sintilimab ...